Predictive Oncology Inc. - Common Stock (POAI)

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END

New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens

PALM BEACH, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a substantial rate for years to come. According to Metastat, Global AI in Diabetic Retinopathy Market is witnessing unprecedented growth, reshaping the landscape of diagnostic and therapeutic interventions for this prevalent and sight-threatening complication of diabetes. As technology continues to advance, artificial intelligence (AI) is emerging as a transformative force in healthcare, particularly in the domain of diabetic retinopathy (DR), where early detection and timely intervention are critical. The report said “AI applications in diabetic retinopathy are gaining momentum due to their ability to augment traditional diagnostic methods. Image analysis, a cornerstone in the detection of retinal abnormalities, has witnessed a paradigm shift with the incorporation of AI algorithms. These algorithms, trained on vast datasets of retinal images, demonstrate remarkable accuracy in identifying subtle changes indicative of diabetic retinopathy. Consequently, they empower healthcare professionals with more efficient and precise tools for early diagnosis. One of the notable contributions of AI in diabetic retinopathy lies in its potential to address the challenge of limited access to ophthalmic expertise, especially in resource-constrained regions. Automated screening processes, driven by AI, enable remote and quick assessment of retinal images, offering a scalable solution to bridge the gap in healthcare accessibility. This democratization of expertise has the potential to revolutionize the way diabetic retinopathy is diagnosed and managed globally.” According to a report issued by Grand View Research: “the global diabetic retinopathy market size was estimated at USD $9.48 Billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion.”   Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Recursion (NASDAQ: RXRX), Tempus AI, Inc. (NASDAQ: TEM), Predictive Oncology Inc. (NASDAQ: POAI), ADMA Biologics, Inc. (NASDAQ: ADMA).

LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States.

Company continues to progress toward the signing of a definitive merger agreement with Renovaro

— FDA Approvals, Deep Mineral Finds, AI-Powered Drug Leads, Global Health Vaccine and Wireless Signals, Solutions Capture Market Attention —

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan

Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth

Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States

Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules.

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced that it has entered into definitive agreements for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 19, 2025, subject to the satisfaction of customary closing conditions.

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types

Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids

Initial plans target European clinical trials while providing standard testing to clinicians for individual patients

NEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Company to Host International Roadshow the Week of January 13, 2025

BALA CYNWYD, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQ: POAI) to Renovaro Inc. is fair to Predictive shareholders.

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data

- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024.

Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value